IVF arrives at its April 30 earnings with the stock down 28% over the past month — a selloff that has reset the bar sharply lower but has also driven a notable shift in borrowing conditions.
The most interesting angle heading into this print is the cost-to-borrow narrative. Borrowing costs have more than halved since mid-March, falling from a peak of around 163% annualised to roughly 55% now — a meaningful easing in a stock that was, until recently, among the most expensive names to short in its peer group. That easing reflects a sharp drop in short interest itself: shares short collapsed roughly 75% through the middle of April, though they have since crept back up about 34% over the past week to sit near 96,000 shares. At just 0.6% of the free float, the short position is not large in absolute terms. The lending pool is far from exhausted — availability is not a constraint here. What stands out instead is the volatility of the positioning, which swung from roughly 430,000 shares short in late March to under 70,000 shares in mid-April, a dislocation that suggests forced covering rather than a deliberate unwind.
Earnings history offers the starkest framing for what this print could produce. All four prior events on record resulted in a negative one-day move — averaging a loss of around 12% on the day, with the worst print in January 2026 delivering an 18.9% one-day drop followed by a 29.9% five-day loss. The November 2025 reading was similarly punishing at –10.6% on the day and –33.2% over the following week. The stock has never, in recent history, rewarded buyers on earnings day. That pattern sits against a price already under pressure at $1.92, down 15% on the week alone.
Institutional ownership is thin and concentrated. Armistice Capital holds 7.5% of shares as of December 2025 — effectively the anchor holder — with Glenbrook Capital the only other meaningful presence at 1.7%. Five Narrow Lane cut its holding by over 45,000 shares in the January filing period. With such a narrow holder base and no analyst coverage visible in the data, there is no Wall Street consensus to push back against bearish price action. The ORTEX short score has nudged higher this week to 67.3, its best reading in the past two weeks, reflecting the recent uptick in short positioning rather than any structural shift in sentiment.
The print will test whether INVO Fertility's commercial progress with its INVOcell fertility platform can offer any offset to a pattern of post-earnings selling that has been consistent across every recent quarter.
See the live data behind this article on ORTEX.
Open IVF on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.